Nearly everyone knows someone living with chronic pain.
Yet this condition remains notoriously difficult to measure, explain or treat. It can follow an acute injury or arrive unprompted, often evading medical scans and leaving patients without the visible evidence that might convince others their pain is real. And doctors still struggle to understand why pain lingers indefinitely in some bodies and dissipates in others.
But a new study, published Thursday in the journal Nature Neuroscience, suggests that some answers could be on the horizon. The analysis — the largest of its kind to date — pooled genetic and health records from more than 1.2 million people across three large biobanks with the aim of mapping the condition’s genetic architecture.
There is no one single “pain gene,” or even a handful of them, said Dr. Stephen Waxman, a neurologist at Yale who studies the genetics of rare pain disorders. (He was not involved in the new study.) Conditions like erythromelalgia, commonly known as “man on fire” syndrome — in which patients feel extreme burning from mild heat sources, like wearing socks — can be driven by a single mutation. But when it comes to common chronic pain, which affects tens of millions of people in the United States alone, thousands of tiny genetic variations interact with environmental factors and one another to influence a patient’s experience.
The sheer size of the data set in the new study allowed scientists to identify 343 different locations on the human genome that were tied to chronic pain, about a quarter of which had not been identified before. It also helped them map how the affected genes play out in the body, looking at the biology of chronic pain in more detail.
The work is still in its foundational stages. Studies of twins and family members have suggested that genes account for about 25 to 50 percent of the variation in chronic pain across a population, but all common genetic variants captured in this analysis still only account for between 5 and 8 percent of that variation. Dr. Henry Kranzler, a professor of psychiatry at the University of Pennsylvania Perelman School of Medicine and one of the study authors, said that with larger and more diverse data sets, the number of known gene variants influencing chronic pain could climb to “what could be 10,000.”
“So we have a long way to go,” he said. “That’s a humbling observation.”
Dr. Kranzler and his colleagues also found that the affected genes were overwhelmingly associated with brain tissue and nerve communication, rather than tissues where people typically experience the pain, such as joint cartilage or muscles. (They also uncovered variants tied to C-reactive protein, a chemical released into the bloodstream during systemic inflammation that tends to be elevated in people suffering from pain.)
The finding should reinforce the medical field’s understanding that chronic pain is not merely a version of acute pain that lingers in tissues after a back or neck injury. Instead, it is a distinct disorder of the central nervous system, in which the brain’s processing systems become hypersensitive or out of sync.
And there was another unexpected lesson in the new data: Between 81 and 93 percent of the genetic variants associated with chronic pain were drawn from the same pool of variants that influence mental health conditions such as depression, post-traumatic stress disorder, insomnia and substance use disorders. This suggests that not only can physical suffering drive people into psychological despair, but the same underlying genetic vulnerabilities may increase a person’s risk for both.
The study had a key limitation: Because two of the three biobanks used were predominantly white, the full analysis was limited to people of European ancestry. In the future, investigators would need to draw upon much more diverse data sets to ensure that their discoveries are relevant for all groups.
Still, scientists are hopeful that this line of research could eventually point toward practical applications and even prevention tactics, particularly in cases where acute, short-term injury threatens to lead to long-term, disabling pain. If genetics could help doctors identify which patients are at highest risk for their pain turning chronic, they could act early, prescribing specialized physical therapy or psychological support before pain-related pathways are locked into the brain.
“If you have surgery, that’s going to be painful — it just is,” Dr. Kranzler said. “But not everyone has the same risk of it becoming chronic pain.”
There are also potential implications for discovering better chronic pain treatments. For example, by matching genes to the proteins they encode — and in turn, the medications that interact with those proteins — scientists could design new drugs, or test existing ones that are already approved for other conditions. The goal would be to identify pain treatments that directly alter the firing patterns of brain circuitry or inflammation pathways, rather than just masking symptoms, as opioids do.
Pharmaceutical companies have typically hesitated to invest in pain-related medical trials because there is no objective test for measuring pain, Dr. Waxman said. Unlike for a cancer drug, for which researchers can track the shrinking diameter of a tumor, pain trials rely on a subjective 0-to-10 scale that can fluctuate with factors like sleep or even the time of day.
Still, scientists hope that uncovering a vast array of genetic targets for the drugs may give companies more interest in taking the financial risk.
“The unmet need is immense,” Dr. Waxman said, “and that translates into an immense market.”
The post What Can Our Genes Reveal About Chronic Pain? appeared first on New York Times.




